Nifedipine Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022 - 2027

Report Code: HCR 64488 Report Format: PDF + Excel

Nifedipine Market Overview

Nifedipine Market size is estimated to reach $1.7 billion by 2027, growing at a CAGR of 4.1% during the forecast period 2022-2027. Nifedipine falls under the category of calcium channel blocker drugs which is widely used to treat complications such as chest pain (angina), Hypertension, preterm labor, Prinzmetal angina (=squeezing of blood vessels), Raynaud’s phenomenon (= numbing of several parts). There are many other dihydropyridine calcium channel blocker drugs including nitrendipine and nisoldipine for treating HBP problems. In recent years, abnormalities like premature labor are emerging and are stirring the demand for the aforementioned drugs. Tocolytics are used to suppress preterm by stopping the contraction of muscles cells. Similarly, nifedipine helps prevent preemies from health hitches that they’re susceptible to by virtue of premature births. Elevating prevalence of health issues like HBP, arrhythmia, and other chronic illnesses are factors set to drive the growth of the Nifedipine Industry for the period 2022-2027.

Report Coverage:

The report: “Nifedipine Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Nifedipine Market.

By Application: HBP, Heart Attack, Chilblain, Cephalalgia, Chest Pain, Preterm Labor, Prinzmetal’s Angina, Raynaud’s Phenomenon.
By Type: capsule (immediate release), extended-release tablet.
By Distribution Channel: Hospital Pharmacies, Medical Centers, Retail Pharmacies.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (the Middle East and Africa).

Key Takeaways:

  • Geographically, the North America Nifedipine Market accounted for the highest revenue share in 2021. However, Asia-Pacific is poised to offer lucrative growth opportunities to marketers in the projected period of 2022-2027.
  • Soaring complications like HBP (=high blood pressure), and cardiovascular ailments which include coronary artery sickness are said to be preeminent drivers driving the growth of the Nifedipine Market. However, side effects accompanied by nifedipine are said to reduce the market growth.
  • Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Nifedipine Market report.

Nifedipine Market- Geography (%) for 2021.

For More Details on This Report - Request for Sample

Nifedipine Market Segment Analysis-By Application

The Nifedipine Market based on the application type can be further segmented into HBP, heart attack, chilblain, cephalalgia, chest pain (angina), preterm labor, prinzmetal’s angina (=squeezing of blood vessels), Raynaud’s phenomenon (= numbing of several parts). The Preterm labor segment held the largest share in 2021. This growth is owing to increasing cases of premature births due to hormonal imbalance or stretching of the uterus. Other than that, various chronic illnesses such as hypertension and diabetes also have their fair share in the prevalence of such sickness.

However, the heart attack and HBP segments are estimated to be the fastest-growing segment with a CAGR of 4.7% over the forecast period 2022-2027. This growth is owing to prevailing obesity cases ascribing to poor diet ingestion, excessive junk food intake, no exercise, growing trend of smoking and alcohol consumption among the younger generation, and stress.

Nifedipine Market Segment Analysis-By Distribution Channel

The Nifedipine Market based on Distribution Channel can be further segmented into hospital pharmacies, medical centers, retail pharmacies. The hospital pharmacy segment held the largest share in 2021. The growth is owing to high demand and rush in hospitals as chronic illnesses are elevating due to rising old-age population, and broadening pollution. Post COVID-19 there has been a precipitous ascension in maladies due to too little to no physical activity during the lockdown. On the other hand, Nifedipine drugs are not available over the counter and require a prescription from doctors which gravitate patients towards hospitals.

Moreover, the Retail pharmacy segment is estimated to be the fastest-growing segment with a CAGR of 4.8% over the forecast period 2022-2027. This growth is owing to the growing presence of retail pharmacy outlets in pastoral areas due to rising drug consumption. In the US, an increment of 12.6% was recorded in the last decade. Owing to such growth, the segment is estimated to offer lucrative growth opportunities.

Nifedipine Market Segment Analysis-By Geography

The Nifedipine Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 35% of the overall market in 2021. The growth in this segment is owing to the factors such as heightening sickness such as heart attack, angina, high blood pressure due to widescale obesity among the American public. In 2021 US-dominated every other country on the planet in terms of obesity rates. Around 36.20% of adults in the US are facing overweight problems which are leading the calcium channel blocker drugs market.

However, Asia-Pacific is expected to be the fastest-growing segment with a CAGR of 35% over the forecast period 2022-2027. This growth is owing to growing chronic maladies due to expanding old-age population especially in countries like India and China, refining healthcare infrastructure as governments are allocating innumerable funds in development.

Nifedipine Market Drivers

Enlarging long-term illnesses are Anticipated to Boost Product Demand.

Trends of using Calcium channel blockers such as Norvasc, Nicardipine, Procardia, and many more have intensified post-COVID-19 with augmentation in acute and chronic health abnormalities. In the US around 332,915,000 adults which account 36.20% face obesity problems. Poor lifestyles of people are pushing them one step closer to illnesses such as high blood pressure, chest pains, heart attacks, etc. Therefore the overall rate of drug consumption is elevating which is stimulating the demand of Nifedipine market.

Elevating demand for calcium channel blocker drugs is Expected to Boost Product Demand.

Nifedipine is an efficient drug for the treatment of various sicknesses such as HBP, heart attack, chilblain, cephalalgia, chest pain (angina), preterm labor, prinzmetal’s angina (=squeezing of blood vessels), Raynaud’s phenomenon (= numbing of several parts). Owing to its effectiveness especially in the treatment of preterm labor, overall consumption of the drug is elevating. It suppresses preterm by stopping the contraction of muscles cells and helps prevent preemies from health hitches that they’re susceptible to by virtue of premature births.

Nifedipine Market Challenges

Health concerns linked accompanied to nifedipine are Anticipated to Hamper Market Growth.

Even though the demand for nifedipine is shooting up but one factor which is anticipated to strangle the growth of this calcium channel blocker drug is many side effects associated with its use. Nausea, rapid increase in weight, tenderness in various parts of the body, irregular beating of the heart. In addition to that, some serious side effects include liver damage, stoppage of breathing. Also, consumption of nifedipine with some antibiotics and antiviral drugs may lead to a rise in the nifedipine level in the body which can lead to serious illnesses.

Nifedipine Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Nifedipine Market. Nifedipine top 10 companies include:

  1. Bayer
  2. Pfizer
  3. AstraZeneca
  4. Shyndec
  5. Actavis
  6. Abbott laboratory
  7. Honglin
  8. Merck
  9. Global pharm
  10. Teva Pharmaceutical Industry Ltd

Recent Developments

  • On April 23, 2021, Germany-based nifedipine producer MNC announced that the supply of 30mg tablets of Adalat LA prolonged-release has been restarted to the UK. Earlier in 2019 due to shortage aforementioned tablets ran out of stock in the UK. Alliance healthcare issues were the prima-facie for production issues, which for now have been rectified. Furthermore, prolonged-release tablets to be the most effective treatment of the various nifedipine products.
  • On September 18, 2019, AVET announced the launch of nifedipine soft gel capsules. The products was being readily available in the potency of 10 and 20mg. This product is the AB-rated generic equivalent to the calcium blocker drug Procardia® and adds to Avet’s robust portfolio of generic oral solid products. Furthermore, the spokesperson regarded that the drug would allow them to compete in the heavily dominated market for hypertension.

Relevant Links:

Blood Pressure Monitoring Devices Market – Forecast (2022 - 2027)

Report Code: HCR 0162

Obesity Management Market – Forecast (2022 - 2027)

Report Code: HCR 0348

For more Lifesciences and Healthcare Market reports, please click here

1. Nifedipine Market Overview
    1.1 Definitions and Scope
2. Nifedipine Market - Executive Summary
3. Nifedipine Market– Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Nifedipine Market– Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Nifedipine Market– Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Nifedipine Market- Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Nifedipine Market– By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Nifedipine Market – By Application (Market Size –$Million/$Billion) 
    8.1 HBP
    8.2 Heart attack
    8.3 Chilblain
    8.4 Cephalalgia
    8.5 Chest pain (angina)
    8.6 Preterm labor
    8.7 Prinzmetal’s angina (=squeezing of blood vessels)
    8.8 Raynaud’s phenomenon (= numbing of several parts).
9. Nifedipine Market - By Type (Market Size –$Million/$Billion) 
    9.1 Capsule (immediate-release)
    9.2 Extended-release tablet.
10. Nifedipine Market – B Distribution Channel (Market Size –$Million/$Billion) 
    10.1 Hospital pharmacies
    10.2 Medical centers
    10.3 Retail pharmacies.
11. Nifedipine Market- By Geography (Market Size -$Million/Billion)
    11.1 North America
        11.1.1 U.S
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 Germany
        11.2.2 France
        11.2.3 UK
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 Japan
        11.3.3 South Korea
        11.3.4 India
        11.3.5 Australia & New Zealand
        11.3.6 Rest of APAC
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Chile
        11.4.4 Colombia
        11.4.5 Rest of South America
    11.5 Rest of World
        11.5.1 Middle East
        11.5.2 Africa
12. Nifedipine Market- Market Entropy
    12.1 New product launches
    12.2 M&A's, collaborations, JVs, and partnerships
13. Nifedipine Market– Industry Competition Landscape (Premium)
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key Companies
        13.1.3 Market Share by Countries – Key Companies
    13.2 Competition Matrix
    13.3 Best Practices for Companies
14. Nifedipine Market– Key Company List by Country Premium (Premium)
15. Nifedipine Market- Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies"

LIST OF TABLES

1.Global Nifedipine , By Product Market 2019-2024 ($M)
1.1 Nifedipine Controlled Release Tablet Market 2019-2024 ($M) - Global Industry Research
1.2 Nifedipine Extended Action Tablet Market 2019-2024 ($M) - Global Industry Research
2.Global Nifedipine , By Product Market 2019-2024 (Volume/Units)
2.1 Nifedipine Controlled Release Tablet Market 2019-2024 (Volume/Units) - Global Industry Research
2.2 Nifedipine Extended Action Tablet Market 2019-2024 (Volume/Units) - Global Industry Research
3.North America Nifedipine , By Product Market 2019-2024 ($M)
3.1 Nifedipine Controlled Release Tablet Market 2019-2024 ($M) - Regional Industry Research
3.2 Nifedipine Extended Action Tablet Market 2019-2024 ($M) - Regional Industry Research
4.South America Nifedipine , By Product Market 2019-2024 ($M)
4.1 Nifedipine Controlled Release Tablet Market 2019-2024 ($M) - Regional Industry Research
4.2 Nifedipine Extended Action Tablet Market 2019-2024 ($M) - Regional Industry Research
5.Europe Nifedipine , By Product Market 2019-2024 ($M)
5.1 Nifedipine Controlled Release Tablet Market 2019-2024 ($M) - Regional Industry Research
5.2 Nifedipine Extended Action Tablet Market 2019-2024 ($M) - Regional Industry Research
6.APAC Nifedipine , By Product Market 2019-2024 ($M)
6.1 Nifedipine Controlled Release Tablet Market 2019-2024 ($M) - Regional Industry Research
6.2 Nifedipine Extended Action Tablet Market 2019-2024 ($M) - Regional Industry Research
7.MENA Nifedipine , By Product Market 2019-2024 ($M)
7.1 Nifedipine Controlled Release Tablet Market 2019-2024 ($M) - Regional Industry Research
7.2 Nifedipine Extended Action Tablet Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Nifedipine Market Revenue, 2019-2024 ($M)
2.Canada Nifedipine Market Revenue, 2019-2024 ($M)
3.Mexico Nifedipine Market Revenue, 2019-2024 ($M)
4.Brazil Nifedipine Market Revenue, 2019-2024 ($M)
5.Argentina Nifedipine Market Revenue, 2019-2024 ($M)
6.Peru Nifedipine Market Revenue, 2019-2024 ($M)
7.Colombia Nifedipine Market Revenue, 2019-2024 ($M)
8.Chile Nifedipine Market Revenue, 2019-2024 ($M)
9.Rest of South America Nifedipine Market Revenue, 2019-2024 ($M)
10.UK Nifedipine Market Revenue, 2019-2024 ($M)
11.Germany Nifedipine Market Revenue, 2019-2024 ($M)
12.France Nifedipine Market Revenue, 2019-2024 ($M)
13.Italy Nifedipine Market Revenue, 2019-2024 ($M)
14.Spain Nifedipine Market Revenue, 2019-2024 ($M)
15.Rest of Europe Nifedipine Market Revenue, 2019-2024 ($M)
16.China Nifedipine Market Revenue, 2019-2024 ($M)
17.India Nifedipine Market Revenue, 2019-2024 ($M)
18.Japan Nifedipine Market Revenue, 2019-2024 ($M)
19.South Korea Nifedipine Market Revenue, 2019-2024 ($M)
20.South Africa Nifedipine Market Revenue, 2019-2024 ($M)
21.North America Nifedipine By Application
22.South America Nifedipine By Application
23.Europe Nifedipine By Application
24.APAC Nifedipine By Application
25.MENA Nifedipine By Application
26.Glaxosmithkline Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Novartis Ag, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Merck Co , Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Abbott Laboratory, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Boehringer Ingelheim Gmbh, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Astrazeneca Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.F. Hoffmann-La Roche Ag, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Teva Pharmaceutical Industry Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Vectura Group Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Pifizer Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)